Stocktoria
DarioHealth Corp. DRIO
DarioHealth Corp. (DRIO) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $22.4M at a -186.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.234 |
| Retained earnings / assets | -4.107 |
| EBIT / assets | -0.333 |
| Equity / liabilities | 1.611 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DRIO | DarioHealth Corp. | 3/9 | -12.4 | — | -17.3% |
| BDMD | Baird Medical Investment Holdings Ltd | 1/9 | 0.49 | — | -39.2% |
| MDAI | Spectral AI, Inc. | 3/9 | -11.78 | — | -33.6% |
| SNOA | Sonoma Pharmaceuticals, Inc. | 2/9 | — | — | +36.7% |
| NEPH | NEPHROS INC | 6/9 | — | 32.8 | +32.7% |
| VVOS | Vivos Therapeutics, Inc. | 2/9 | — | — | +16% |
| SRTS | Sensus Healthcare, Inc. | 4/9 | 14.36 | — | -34.3% |
About DarioHealth Corp.
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1. It also provides bundled full-suite or partial-suite subscriptions. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
FAQ
Is DRIO financially healthy?
DarioHealth Corp.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does DRIO pay a dividend?
No, DarioHealth Corp. does not currently pay a dividend.
How profitable is DRIO?
In FY2025, DarioHealth Corp. had a net margin of -186.6% and a return on equity of -61.4%.
Is DRIO overvalued or undervalued?
DarioHealth Corp. trades at about 0.7× trailing earnings — below its 10-year norm (10-year range 1.0×–108.0×, median 43.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for DRIO?
The average Wall-Street price target for DarioHealth Corp. is $18.50, about 147.3% above the recent price, from 4 analysts.
Is DRIO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DarioHealth Corp.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.